Franklin Biotechnology Discovery Fund Advisor Class (FTDZX)

Fund Assets	1.42B
Expense Ratio	0.80%
Min. Investment	$1,000
Turnover	n/a
Dividend (ttm)	11.76
Dividend Yield	9.88%
Dividend Growth	n/a
Payout Frequency	n/a
Ex-Dividend Date	Dec 20, 2024

Previous Close	119.64
YTD Return	-6.20%
1-Year Return	-3.28%
5-Year Return	1.64%
52-Week Low	n/a
52-Week High	n/a
Beta (5Y)	n/a
Holdings	92
Inception Date	Sep 1, 2009

About FTDZX

The Franklin Biotechnology Discovery Fund Advisor Class (FTDZX) seeks to provide capital appreciation. Under normal market conditions, the Fund predominantly invests in equity securities and invests at least 80% of its net assets in securities of biotechnology companies(at least 50% of its earnings derived from biotechnology activities) and discovery research firms.

• Fund Family: FrankTemp/Frank Adv
• Category: Health
• Performance Rating: Average
• Risk Rating: Above Average
• Stock Exchange: NASDAQ
• Ticker Symbol: FTDZX
• Share Class: Advisor Class
• Index: NASDAQ Biotechnology CR

Performance

FTDZX had a total return of -3.28% in the past year, including dividends. Since the fund's inception, the average annual return has been 9.76%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
FRBRX	Class R6	0.69%
FBDIX	Class A	1.05%
FBTDX	Class C	1.80%

Top 10 Holdings

50.13% of assets

Name	Symbol	Weight
Amgen Inc.	AMGN	8.11%
Gilead Sciences, Inc.	GILD	7.82%
Vertex Pharmaceuticals Incorporated	VRTX	7.75%
Regeneron Pharmaceuticals, Inc.	REGN	5.50%
Ascendis Pharma A/S	ASND	4.42%
Jazz Pharmaceuticals plc	JAZZ	4.10%
argenx SE	ARGX	3.80%
PTC Therapeutics, Inc.	PTCT	3.13%
Merus N.V.	MRUS	2.93%
Neurocrine Biosciences, Inc.	NBIX	2.57%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 20, 2024	$11.7607	Dec 20, 2024
Dec 20, 2022	$0.4163	Dec 20, 2022
Dec 15, 2021	$18.0843	Dec 15, 2021
Dec 15, 2020	$10.3921	Dec 15, 2020
Dec 16, 2019	$14.1643	Dec 18, 2019
Dec 17, 2018	$4.5496	Dec 19, 2018